공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

메티실린 감수성 황색 포도상구균(MSSA) 감염증 : 파이프라인 리뷰

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 09월 상품 코드 271821
페이지 정보 영문 67 Pages
가격
US $ 2,000 ₩ 2,367,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,735,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,102,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


메티실린 감수성 황색 포도상구균(MSSA) 감염증 : 파이프라인 리뷰 Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) - Drugs in Development, 2021
발행일 : 2021년 09월 페이지 정보 : 영문 67 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

메티실린 감수성 황색 포도상구균(MSSA)은 여러가지 항생제에 대한 내성을 가진 세균입니다. MSSA는 보통 피부에 감염되는데, 폐렴이나 그 외 심각한 감염증을 일으킬 수 있습니다. 봉와직염, 통증을 동반한 발진, 오심, 구토, 발열, 근육통, 설사나 복통 등의 증상이 나타나며, 발병 요인에는 면역 시스템 약화, 화상, 수술에 의한 상처 등이 있습니다.

메티실린 감수성 황색 포도상구균(MSSA) 감염증(Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections) 치료제 개발 상황에 대해 조사 분석했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 약제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등의 정보를 전해드립니다.

서론

  • 조사 범위

메티실린 감수성 황색 포도상구균(MSSA) 감염증 개요

치료제 개발

  • 파이프라인 제품 개요
  • 기업별 파이프라인
  • 대학/연구기관별 파이프라인
  • 기업에서 개발중인 제품
  • 대학/연구기관에서 개발중인 제품

치료제 평가

  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

치료제 개발에 참여하고 있는 기업

  • Antibiotx ApS
  • ContraFect Corp
  • Debiopharm International SA
  • Sealife PHARMA GMBH

약제 개요

휴지중인 프로젝트

개발이 중지된 제품

제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

KSM 17.07.24

List of Tables

List of Tables

  • Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Basilea Pharmaceutica Ltd, 2021
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by BioPlx Microbiomics Pvt Ltd, 2021
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Debiopharm International SA, 2021
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Destiny Pharma Plc, 2021
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Galenus Therapeutics Inc, 2021
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Genentech USA Inc, 2021
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by HyPharm GmbH, 2021
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by LegoChem Biosciences Inc, 2021
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Lytix Biopharma AS, 2021
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Naicons Srl, 2021
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Sichuan Saizhuo Pharmaceutical Co Ltd, 2021
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Dormant Projects, 2021
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Targets, 2021
  • Number of Products by Stage and Targets, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Susceptible Staphylococcus aureus Infections - Drugs In Development, 2021, provides an overview of the Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease) pipeline landscape.Methicillin-Susceptible Staphylococcus aureus (MSSA) is a bacterium that is resistant to many antibiotics. MSSA usually cause skin infections, but can also cause pneumonia, and other serious types of infections. Symptoms include cellulitis, painful rashes, nausea and vomiting, fever, muscle aches, diarrhea and abdominal pain. Predisposing factors include weakened immune systems, burns and surgical wounds.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Methicillin-Susceptible Staphylococcus aureus Infections - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 1, 1, 4, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.

Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Methicillin-Susceptible Staphylococcus aureus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Overview
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Companies Involved in Therapeutics Development
  • Basilea Pharmaceutica Ltd
  • BioPlx Microbiomics Pvt Ltd
  • Debiopharm International SA
  • Destiny Pharma Plc
  • Galenus Therapeutics Inc
  • Genentech USA Inc
  • HyPharm GmbH
  • LegoChem Biosciences Inc
  • Lytix Biopharma AS
  • Naicons Srl
  • Sichuan Saizhuo Pharmaceutical Co Ltd
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Drug Profiles
  • afabicin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BioPlx-01KS - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BioPlx-01WT - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ceftobiprole medocaril - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • exeporfinium chloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GTX-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HY-133 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LCB-010699 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • litazolid - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LTX-109 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NAI-108 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RG-7861 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules for Bacterial Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit DNA Gyrase and DNA Topoisomerase IV for Bacterial Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • targocil - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Dormant Projects
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Discontinued Products
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Product Development Milestones
  • Featured News & Press Releases
  • Apr 20, 2018: Basilea reports presentations of ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
  • Apr 12, 2018: Cardiome Presents Zevtera Abstracts at ECCMID 2018
  • Mar 22, 2018: Sichuan Saizhuo Pharmaceutical obtained the clinical approval for a new drug "Ristazolone Dry Suspension"
  • Apr 21, 2017: Basilea announces agreement with FDA on Special Protocol Assessments for antibiotic ceftobiprole phase 3 clinical studies in bloodstream and skin infections
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q